Extended-release wax-matrix nicotinic acid supports lipid metabolism, study shows
Highlights
- Comparison study (n=93 adults)
- Long-term use supports lipid metabolism
- Effective dosage: 1,500 mg/day for 16-24 weeks
Summary
This comparison study explores the relative efficacy of long-term use of extended-release, wax-matrix nicotinic acid (WMNA) or a fibrate drug in combination with a heart healthy diet for treatment of hyperlipidemia in patients with ischemic heart disease.
For this study, researchers enrolled 93 patients, aged 50-65 years. The use of WMNA (1,500 mg/day) for 16-24 weeks reduced cholesterol by 16%, low density lipoproteins by 19%, and triglycerides by 26%, and increased high density lipoproteins by 16%. The fibrate drug Besafibrat (Germany), given at a dose indicated for isolated hypertriglyceridemia (600 mg/day) reduced triglycerides by 41%. Diet alone had no significant effect on lipid profiles.
These findings indicate WMNA is an effective treatment for hyperlipidemia in patients with ischemic heart disease, especially if fibrates are contraindicated.
